The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Solubility Advantage of Pharmaceutical Cocrystals
Abstract
Pharmaceutical cocrystals can improve solubility, dissolution, and bioavailability of poorly water soluble drugs. However, true cocrystal solubility is not readily measured for highly soluble cocrystals because they can transform to the most stable drug form in solution. The objectives of this study are to develop a method to estimate the cocrystal solubility in pure solvent and establish the influence of constituent drug and ligand (i.e., coformer) properties. Cocrystal solubility and solubility product were derived from transition concentration measurements where a solution is in equilibrium with solid drug and cocrystal. Transition concentrations and solubilities are reported for carbamazepine cocrystals in water, ethanol, isopropanol, and ethyl acetate. The aqueous solubility for seven carbamazepine cocrystals was estimated to be 2−152 times greater than the solubility of the stable carbamazepine dihydrate form. Cocrystal solubility is shown to be directly proportional to the solubility of constituent reactants for carbamazepine, caffeine, and theophylline cocrystals. The ligand transition concentration is also correlated with ligand solubility. Transition concentration measurements reveal drug solubilization by ligand for several of the cocrystals studied. The correlation established between constituent and cocrystal solubility was not effectively predicted by fusion properties of the various crystal forms considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Encyclopedia of pharmaceutical technology
(2003) · Choice Reviews Online · doi:10.5860/choice.40-6157 · Cited by 1,743
What is the True Solubility Advantage for Amorphous Pharmaceuticals?
Hancock, B. C., & Parks, M. (2000) · Pharmaceutical Research · doi:10.1023/a:1007516718048 · Cited by 1,358
Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API
McNamara, D. P., Childs, S. L., Giordano, J., Iarriccio, A., Cassidy, J., Shet, M. S., Mannion, R., O'Donnell, E., & Park, A. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9032-3 · Cited by 690
Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L. X., & Amidon, G. L. (2006) · Molecular Pharmaceutics · doi:10.1021/mp0600182 · Cited by 606
Trends in Solubility of Polymorphs
Pudipeddi, M., & Serajuddin, A. T. M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20302 · Cited by 505
General principles of pharmaceutical solid polymorphism A supramolecular perspective
Rodriguez‐Spong, B., Price, C. P., Jayasankar, A., Matzger, A. J., & Rodríguez‐Hornedo, N. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.005 · Cited by 455
Self-citationPharmaceutical preformulation : the physicochemical properties of drug substances
Wells, J. I. (1988) · E. Horwood , Halsted Press eBooks · Cited by 298
Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals
Stanton, M. K., & Bak, A. (2008) · Crystal Growth & Design · doi:10.1021/cg800173d · Cited by 236
Bak, A., Gore, A., Yanez, E., Stanton, M., Tufekcic, S., Syed, R., Akrami, A., Rose, M., Surapaneni, S., Bostick, T., et al. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21280 · Cited by 218
Cited by
Metal–Organic Frameworks in Biomedicine
Horcajada, P., Gref, R., Baati, T., Allan, P. K., Maurin, G., Couvreur, P., Férey, G., Morris, R. E., & Serre, C. (2012) · Chemical Reviews · doi:10.1021/cr200256v · Cited by 4,168
Mechanochemistry: opportunities for new and cleaner synthesis
James, S. L., Adams, C. J., Bolm, C., Braga, D., Collier, P., Friščić, T., Grepioni, F., Harris, K. D. M., Hyett, G., Jones, W., et al. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15171a · Cited by 3,056
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
Babu, N. J., & Nangia, A. (2011) · Crystal Growth & Design · doi:10.1021/cg200492w · Cited by 1,004
Acid–base crystalline complexes and the pKa rule
Cruz-Cabeza, A. J. (2012) · CrystEngComm · doi:10.1039/c2ce26055g · Cited by 673
Creating Cocrystals: A Review of Pharmaceutical Cocrystal Preparation Routes and Applications
Karimi-Jafari, M., Padrela, L., Walker, G. M., & Croker, D. M. (2018) · Crystal Growth & Design · doi:10.1021/acs.cgd.8b00933 · Cited by 667
Pharmaceutical cocrystals and poorly soluble drugs
Thakuria, R., Delori, A., Jones, W., Lipert, M. P., Roy, L., & Rodríguez-Hornedo, N. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.10.043 · Cited by 614
Self-citationBerry, D. J., & Steed, J. W. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.003 · Cited by 406
Pharmaceutical cocrystals: from serendipity to design to application
Kavanagh, O. N., Croker, D. M., Walker, G. M., & Zaworotko, M. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.023 · Cited by 323
Recent advances of discrete coordination complexes and coordination polymers in drug delivery
Ma, Z., & Moulton, B. (2011) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2011.01.031 · Cited by 310
Sanphui, P., Devi, V. K., Clara, D., Malviya, N., Ganguly, S., & Desiraju, G. R. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00020 · Cited by 282
Acree, W., & Chickos, J. S. (2016) · Journal of Physical and Chemical Reference Data · doi:10.1063/1.4948363 · Cited by 258
Metadata
- Authors
- Good, D. J., & Rodríguez-Hornedo, N.
- Venue
- Crystal Growth & Design
- Publisher
- American Chemical Society (ACS)
- Published
- 2009-03-20
- Volume
- 9
- Issue
- 5
- Pages
- 2252-2264
- ISSN
- 1528-7483 (ISSN-L)
- 1528-7505
- OpenAlex
- W2024071582
- Cited by
- 841
- References
- 19
- FWCI
- 21.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.